Cargando…
Lower serum interleukin‐22 and interleukin‐35 levels are associated with disease status in neuromyelitis optica spectrum disorders
AIMS: The exact pathogenesis of neuromyelitis optica spectrum disorder (NMOSD) remains unclear. A variety of cytokines are involved, but few studies have been performed to explore the novel roles of interleukin‐22 (IL‐22) and interleukin‐35 (IL‐35) in NMOSD. Therefore, this study was designed to inv...
Autores principales: | Yang, Hong, Han, Lu, Zhou, Yun‐Jia, Ding, Jie, Cai, Yu, Hong, Rong‐Hua, Hao, Yong, Zhu, De‐Sheng, Shen, Xia‐Feng, Guan, Yang‐Tai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978267/ https://www.ncbi.nlm.nih.gov/pubmed/31342670 http://dx.doi.org/10.1111/cns.13198 |
Ejemplares similares
-
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020) -
Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice
por: Li, Zhiguo, et al.
Publicado: (2018) -
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014) -
Comprehensive Analysis of N(6)-Methyladenosine (m(6)A) Methylation in Neuromyelitis Optica Spectrum Disorders
por: Yang, Hong, et al.
Publicado: (2021) -
The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder
por: Maghbooli, Zhila, et al.
Publicado: (2021)